PL1991225T3 - Zastosowanie deferypronu i sposobów w leczeniu i/lub zapobieganiu ataksji Friedreicha związanej z wewnątrzkomórkową nieprawidłową gospodarką żelazem - Google Patents

Zastosowanie deferypronu i sposobów w leczeniu i/lub zapobieganiu ataksji Friedreicha związanej z wewnątrzkomórkową nieprawidłową gospodarką żelazem

Info

Publication number
PL1991225T3
PL1991225T3 PL07701800T PL07701800T PL1991225T3 PL 1991225 T3 PL1991225 T3 PL 1991225T3 PL 07701800 T PL07701800 T PL 07701800T PL 07701800 T PL07701800 T PL 07701800T PL 1991225 T3 PL1991225 T3 PL 1991225T3
Authority
PL
Poland
Prior art keywords
deferiprone
treat
iron
methods
friedreich ataxia
Prior art date
Application number
PL07701800T
Other languages
English (en)
Inventor
Arnold Munnich
Michael Spino
Ioav Cabantchik
Original Assignee
Apotex Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Tech Inc filed Critical Apotex Tech Inc
Publication of PL1991225T3 publication Critical patent/PL1991225T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07701800T 2006-02-22 2007-02-21 Zastosowanie deferypronu i sposobów w leczeniu i/lub zapobieganiu ataksji Friedreicha związanej z wewnątrzkomórkową nieprawidłową gospodarką żelazem PL1991225T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77532006P 2006-02-22 2006-02-22
EP07701800.0A EP1991225B1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
PCT/CA2007/000252 WO2007095728A1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Publications (1)

Publication Number Publication Date
PL1991225T3 true PL1991225T3 (pl) 2014-04-30

Family

ID=38436879

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07701800T PL1991225T3 (pl) 2006-02-22 2007-02-21 Zastosowanie deferypronu i sposobów w leczeniu i/lub zapobieganiu ataksji Friedreicha związanej z wewnątrzkomórkową nieprawidłową gospodarką żelazem

Country Status (24)

Country Link
US (3) US20090023784A1 (pl)
EP (1) EP1991225B1 (pl)
JP (1) JP5730466B2 (pl)
KR (1) KR20080104329A (pl)
CN (1) CN101420954A (pl)
AU (1) AU2007219009B2 (pl)
BR (1) BRPI0708211A2 (pl)
CA (1) CA2642778A1 (pl)
DK (1) DK1991225T3 (pl)
ES (1) ES2441065T3 (pl)
IL (1) IL193598A (pl)
MA (1) MA30266B1 (pl)
MX (1) MX2008010824A (pl)
MY (1) MY151412A (pl)
NZ (1) NZ570730A (pl)
PL (1) PL1991225T3 (pl)
PT (1) PT1991225E (pl)
RS (1) RS53225B (pl)
RU (1) RU2008137604A (pl)
SG (1) SG170020A1 (pl)
SI (1) SI1991225T1 (pl)
TN (1) TNSN08338A1 (pl)
UA (1) UA95099C2 (pl)
WO (1) WO2007095728A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080104329A (ko) * 2006-02-22 2008-12-02 아놀드 뮤니히 데페리프론의 이용 및 철의 세포 내 미스핸들링으로부터 비롯된 프리드리히 운동실조증의 치료 및/또는 예방 방법
US8026261B2 (en) 2007-03-28 2011-09-27 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
DK2268282T3 (en) 2008-04-25 2014-11-24 Apotex Technologies Inc Liquid formulation of deferiprone with pleasant taste
EP2389179A4 (en) 2009-01-26 2012-08-29 Michael Spino USE OF DEFERPRONE FOR THE TREATMENT AND PREVENTION OF IRON-RELATED EYE DISORDERS
SI2448922T1 (sl) 2009-07-03 2014-12-31 Apotex Technologies Inc. Fluorirani derivati 3-hidroksipiridin-4-onov
CN102573842A (zh) 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2012028961A2 (en) * 2010-08-30 2012-03-08 Roberto Testi Compositions and methods for treating friedreich's ataxia with interferon gamma
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
WO2013139931A1 (en) * 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
CA3172668A1 (en) 2017-10-25 2019-05-02 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624807A (en) * 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6133322A (en) * 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
EP1565185A4 (en) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
KR20080104329A (ko) * 2006-02-22 2008-12-02 아놀드 뮤니히 데페리프론의 이용 및 철의 세포 내 미스핸들링으로부터 비롯된 프리드리히 운동실조증의 치료 및/또는 예방 방법

Also Published As

Publication number Publication date
ES2441065T3 (es) 2014-01-31
NZ570730A (en) 2013-05-31
CA2642778A1 (en) 2007-08-30
BRPI0708211A2 (pt) 2011-05-17
SG170020A1 (en) 2011-04-29
AU2007219009B2 (en) 2012-12-20
US20070197649A1 (en) 2007-08-23
KR20080104329A (ko) 2008-12-02
JP5730466B2 (ja) 2015-06-10
TNSN08338A1 (en) 2009-12-29
RU2008137604A (ru) 2010-03-27
MX2008010824A (es) 2009-06-08
JP2009527506A (ja) 2009-07-30
EP1991225A4 (en) 2009-07-29
US20090023784A1 (en) 2009-01-22
EP1991225A1 (en) 2008-11-19
US20130190365A1 (en) 2013-07-25
MY151412A (en) 2014-05-30
PT1991225E (pt) 2014-02-13
EP1991225B1 (en) 2013-11-06
CN101420954A (zh) 2009-04-29
SI1991225T1 (sl) 2014-02-28
MA30266B1 (fr) 2009-03-02
WO2007095728A1 (en) 2007-08-30
AU2007219009A1 (en) 2007-08-30
IL193598A (en) 2012-08-30
DK1991225T3 (da) 2013-12-16
RS53225B (en) 2014-08-29
IL193598A0 (en) 2009-08-03
UA95099C2 (ru) 2011-07-11

Similar Documents

Publication Publication Date Title
IL193598A0 (en) The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
IL242169A0 (en) Activin actriia antagonists and uses for the treatment or prevention of breast cancer
EG25839A (en) Consolidating agent emulsions and associated methods
EP2019675A4 (en) METHODS FOR TREATING OR PREVENTING NEOPLASIA
IL197276A0 (en) Methods of inhibiting angiogenesis and treating angiogenesis associated diseases
EP1981491A4 (en) COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DROUGHT
PT2318033T (pt) Composições para o tratamento de dor e/ou inflamação
EP2287155A4 (en) ACYLTHIOURE COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR SALT
EP2060264A4 (en) AGENT FOR TREATING OCULAR DISEASES
EP2214664A4 (en) BRCA1 BASED MEANS FOR THE PREVENTION OF MOM OR OVARIAN CARCINOMA AND METHOD OF ADMINISTRATION
ZA200901553B (en) Pest control agent in form of stable suspension
BRPI1011818A2 (pt) "método de tratamento de câncer com antagonista de dll4 e agente quimioterapêutico"
EP2268281A4 (en) THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS
EP2515926A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS-RELATED OPHTHALMIC DISEASES
HK1151241A1 (en) Enhancement of the efficacy of therapeutic proteins
PL1863435T3 (pl) Zwiększone dostarczanie środków korzystnych dla skóry
IL200966A0 (en) Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
ZA200707487B (en) Enhanced delivery of skin benefit agents
IL207428A0 (en) Agents for treating and/or avoiding fire blight
EP2059621A4 (en) TEMPERATURE STABLE CAST ALLOY AND USE THEREOF
EP2115464A4 (en) METHOD AND COMPOSITIONS FOR DETERMINING THE EFFECT OF BREAST CANCER THERAPEUTICS
GB0703634D0 (en) Treatment of white inorganic ores
ZA201006660B (en) "agent for preventing and/or treating vascular diseases"
GB0814580D0 (en) herbicidal composition and method of use thereof